PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Rivus presents results from trial evaluating controlled metabolic accelerator

HU6 data demonstrates significant selective weight loss across all body compartments.

Rivus – a company specialising in improving cardio-metabolic health – has announced results from its phase 2a trial evaluating the safety and efficacy of its HU6 candidate.

The therapy is a controlled metabolic accelerator (CMA), to address liver fat and total body fat in patients with non-alcoholic fatty liver disease (NAFLD), while the metabolic trial was a 61-day randomised, double-blind, placebo-controlled study that researched the treatment at a variety of doses. Indeed, the trial is the first clinical study that features extended dosing of HU6 in subjects with high body mass index.

The study successfully met its primary target, of liver fat reduction, and multiple secondary endpoints including body weight and fat reduction by abdominal MRI. HU6 was also associated with significant reductions in liver fat as well as total body fat in patients with NAFLD.

Furthermore, patients treated with HU6 demonstrated significant improvement in key cardiovascular and metabolic health indicators including glycemic control and inflammatory markers.

“Obesity is the underlying driver of a broad range of cardio-metabolic conditions including NAFLD,” explained Shaharyar Khan, chief scientific officer at Rivus. “The phase 2a trial results showed that HU6, a first-in-class CMA, stands alone in its mechanism for fat selective weight loss, meeting the primary endpoint for reducing liver fat, as well as reducing body fat in the treated population.

“These results set up the next phase of HU6 clinical development in cardio-metabolic disease, including a phase 2a trial in obese patients with heart failure with preserved ejection fraction, which is currently enrolling, and a phase 2b trial in obesity that will begin enrolment in 2023,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026